Nivolumab for previously treated nonsquamous non-small-cell lung cancer

1 Nov 2017
The National Institute for Health and Care Excellence (NICE)
Patients and public
Type of resource: 

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients.


Click here to read the Guidance in full